Eiger Biopharmaceuticals 55336VAL4 Bond
EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Eiger Biopharmaceuticals holds a debt-to-equity ratio of 0.382. . Eiger Biopharmaceutica's financial risk is the risk to Eiger Biopharmaceutica stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Eiger Biopharmaceutica's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Eiger Biopharmaceutica's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Eiger Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Eiger Biopharmaceutica's stakeholders.
For most companies, including Eiger Biopharmaceutica, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Eiger Biopharmaceuticals, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Eiger Biopharmaceutica's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Eiger |
Given the importance of Eiger Biopharmaceutica's capital structure, the first step in the capital decision process is for the management of Eiger Biopharmaceutica to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Eiger Biopharmaceuticals to issue bonds at a reasonable cost.
Popular Name | Eiger Biopharmaceutica MPLX LP 52 |
Equity ISIN Code | US28249U1051 |
Bond Issue ISIN Code | US55336VAL45 |
S&P Rating | Others |
Maturity Date | 1st of March 2047 |
Issuance Date | 10th of February 2017 |
Coupon | 5.2 % |
Eiger Biopharmaceuticals Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
EIGPRL 3545 31 AUG 36 | US28249NAA90 | Details | |
EIGPRL 4387 30 NOV 46 | US28249NAB73 | Details | |
MGM Resorts International | US552953CD18 | Details |
Understaning Eiger Biopharmaceutica Use of Financial Leverage
Eiger Biopharmaceutica's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Eiger Biopharmaceutica's current equity. If creditors own a majority of Eiger Biopharmaceutica's assets, the company is considered highly leveraged. Understanding the composition and structure of Eiger Biopharmaceutica's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Eiger Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 51 people. Please read more on our technical analysis page.
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
0.82 | BKRKY | Bank Rakyat | PairCorr |
0.82 | PPERY | Bank Mandiri Persero | PairCorr |
0.68 | PPERF | Bank Mandiri Persero | PairCorr |
Moving against Eiger Stock
0.82 | BAC | Bank of America Aggressive Push | PairCorr |
0.74 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
0.72 | CVX | Chevron Corp Sell-off Trend | PairCorr |
0.64 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
0.63 | DIS | Walt Disney Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Global Correlations Find global opportunities by holding instruments from different markets |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.